Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada.
Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada; Institut de Cardiologie de Montréal, Montréal, Québec, Canada.
Can J Cardiol. 2014 Dec;30(12):1576-82. doi: 10.1016/j.cjca.2014.08.010. Epub 2014 Aug 22.
After the approval of transcatheter aortic valve replacement (TAVR) for high-risk or inoperable patients with severe aortic stenosis (AS), many low- and moderate-volume TAVR programs were initiated. Contemporary outcomes from these newly initiated centres remain unknown.
In March 2013, our institution was authorized by the Québec Ministry of Health to perform 30 TAVR procedures. After thorough clinical screening and imaging evaluation, suitable patients underwent transfemoral TAVR with the balloon-expandable SAPIEN XT (Edwards Lifesciences, Irvine, CA) transcatheter heart valve (THV). In-hospital and 30-day outcomes were prospectively collected and reported according to Valve Academic Research Consortium 2 guidelines.
From April 2013 to January 2014, 30 consecutive high-risk (n = 16 [53.3%]) or inoperable (n = 14 [46.7%]) patients (mean age, 84.6 years; mean Society of Thoracic Surgery score, 7) with symptomatic severe AS underwent transfemoral TAVR. No catastrophic intraprocedural complications such as annulus rupture, valve embolization, aortic dissection, or coronary occlusion occurred, and there were no deaths at 30 days. Disabling stroke occurred in 1 (3.3%) patient 48 hours after THV implantation. Major vascular complications and major bleeding occurred in 1 (3.3%) patient. No moderate or severe paravalvular leak was observed. The median length of stay was 2 (1-3) days, with 8 (26.7%) patients discharged within 24 hours after the procedure.
Excellent outcomes can be achieved in newly initiated relatively low-volume centres, which compares favorably to previously published large series. Important considerations include appropriate team training, rigorous patient screening, use of multimodality imaging techniques, a heart team approach, constant integration of lessons learned from larger published experiences, and maintaining a recommended minimum volume of 25 cases per year.
经批准,经导管主动脉瓣置换术(TAVR)可用于治疗高危或手术高危的严重主动脉瓣狭窄(AS)患者。此后,许多低容量和中容量 TAVR 项目开始启动。这些新启动中心的当代结果尚不清楚。
2013 年 3 月,我们的机构获得魁北克省卫生部的授权,可开展 30 例 TAVR 手术。经过彻底的临床筛查和影像学评估,合适的患者接受经股动脉 TAVR,使用球囊扩张的 SAPIEN XT(爱德华兹生命科学公司,加利福尼亚州欧文)经导管心脏瓣膜(THV)。根据 Valve Academic Research Consortium 2 指南,前瞻性收集并报告住院期间和 30 天的结果。
2013 年 4 月至 2014 年 1 月,30 例连续的高危(n=16[53.3%])或手术高危(n=14[46.7%])有症状的严重 AS 患者(平均年龄 84.6 岁;平均胸外科手术评分 7 分)接受了经股动脉 TAVR。没有发生灾难性的术中并发症,如瓣环破裂、瓣膜栓塞、主动脉夹层或冠状动脉阻塞,30 天内无死亡。THV 植入后 48 小时,1 例(3.3%)患者发生致残性卒中。1 例(3.3%)患者发生主要血管并发症和大出血。无中度或重度瓣周漏。中位住院时间为 2(1-3)天,8 例(26.7%)患者在术后 24 小时内出院。
在新启动的低容量中心可取得良好的结果,与之前发表的大型系列研究结果相当。重要的考虑因素包括适当的团队培训、严格的患者筛选、多模态影像学技术的使用、心脏团队方法、不断整合从较大的已发表经验中吸取的教训,以及维持每年推荐的 25 例最低病例量。